Brand Reference: Quviviq
| Metric | Verified Benchmark | Source |
|---|---|---|
| Daridorexant Hydrochloride RxNorm Concept ID | 2590944 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $16.4000 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $524.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $99.00 / mo (Direct TeleMed) | Direct Telehealth Formulary |
| Community Mean Out-of-Pocket Paid | $110.00 / mo | 19 Zero-PHI Verified Patient Logs |
Equipotently blocks neuropeptide orexin-A and orexin-B binding at lateral hypothalamic OX1R and OX2R G-protein receptors, turning down hyperactive wakefulness drive rather than forcing global cortical GABA-A sedation—engineered specifically with an 8-hour half-life to clear by morning.
Across 19 community cost disclosures for Daridorexant Hydrochloride (Quviviq), cash buyers routing around $524.00 retail markups capture a 79% discount ($110.00/mo benchmark vs $16.4000 NADAC acquisition).
Following administration (25 mg PO within 30 min of bedtime (>=7h before wake)), Daridorexant Hydrochloride achieves 62% oral bioavailability and 30 minutes within night 1; improves further over weeks 1–4 onset, governed by a ~8 hours (optimized to prevent next-morning psychomotor impairment) terminal half-life through 89% hepatic cyp3a4 metabolism; fecal biliary clearance.
Before initiating Daridorexant Hydrochloride at 25 mg PO within 30 min of bedtime (>=7h before wake), clinical safety checklists rule out narcolepsy (orexin-deficient state); concomitant strong cyp3a4 inhibitors (itraconazole/clarithromycin). Logged tolerability patterns center on vivid cinematic rem dreams (21% of reports), headache (7% of reports), rare sleep-onset paralysis (<1%) (2% of reports).
Across 19 verified cash-pay logs, Daridorexant Hydrochloride achieves a 88.60% Worth-It rating with out-of-pocket spend averaging $110.00/mo versus $524.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cash Clinic at 25 mg PO within 30 min of bedtime (>=7h before wake) for Daridorexant Hydrochloride; monthly out-of-pocket dropped to $96.80 compared with $524.00 retail.
Completed 10 weeks on Daridorexant Hydrochloride (50 mg PO QHS). Zero notable side effects on steady dosing.
Consistent biomarker response on 25 mg PO within 30 min of bedtime (>=7h before wake) Daridorexant Hydrochloride sourced via Local Pharmacy ($127.60/mo cash pay without insurance prior authorization).